The Cheeky Study: A Novel Delivery System for CAB-RPV LA

计划入组 50 人 · 首次发布于 2023 年 8 月 7 日

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

计划入组 75 人 · 首次发布于 2024 年 6 月 11 日

Improving Treatment and Retention Adherence in Nontraditional Settings

计划入组 25 人 · 首次发布于 2021 年 7 月 22 日

Linoleic acid

C₁₈H₃₂O₂

CAB-051

CAB-02003

Stem Cell Medicine Ltd.

Israel

Sprout Pharmaceuticals, Inc.

United States

BioAtla

United States

ViiV Healthcare Presents Real-World Data on Long-Acting HIV Treatments at IAS 2025

ViiV Healthcare Advances Ultra Long-Acting HIV Pipeline with Third-Generation Integrase Inhibitor VH184 Data at CROI 2026

ViiV Healthcare Showcases Long-Acting HIV Innovations and Pipeline Advances at CROI 2025